Virus-specific T-cell Therapies for Patients with Primary Immune Deficiency

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2020 Jan 17

PMID 31942610

Citations 29

Authors

Michael D Keller

Catherine M Bollard

Affiliations

Soon will be listed here.

Abstract

Viral infections are common and are potentially life-threatening in patients with moderate to severe primary immunodeficiency disorders. Because T-cell immunity contributes to the control of many viral pathogens, adoptive immunotherapy with virus-specific T cells (VSTs) has been a logical and effective way of combating severe viral disease in immunocompromised patients in multiple phase 1 and 2 clinical trials. Common viral targets include cytomegalovirus, Epstein-Barr virus, and adenovirus, though recent published studies have successfully targeted additional pathogens, including HHV6, BK virus, and JC virus. Though most studies have used VSTs derived from allogenic stem cell donors, the use of banked VSTs derived from partially HLA-matched donors has shown efficacy in multicenter settings. Hence, this approach could shorten the time for patients to receive VST therapy thus improving accessibility. In this review, we discuss the usage of VSTs for patients with primary immunodeficiency disorders in clinical trials, as well as future potential targets and methods to broaden the applicability of virus-directed T-cell immunotherapy for this vulnerable patient population.

Citing Articles

Secondary bone marrow graft loss after third-party virus-specific T cell infusion: Case report of a rare complication.

Keller M, Schattgen S, Chandrakasan S, Allen E, Jensen-Wachspress M, Lazarski C Nat Commun. 2024; 15(1):2749.

PMID: 38553461 PMC: 10980733. DOI: 10.1038/s41467-024-47056-3.

The Emerging Role of Induced Pluripotent Stem Cells as Adoptive Cellular Immunotherapeutics.

Mehra V, Chhetri J, Ali S, Roddie C Biology (Basel). 2023; 12(11).

PMID: 37998018 PMC: 10669440. DOI: 10.3390/biology12111419.

Umbilical cord blood derived cellular therapy: advances in clinical development.

Wang J, Metheny L Front Oncol. 2023; 13:1167266.

PMID: 37274288 PMC: 10232824. DOI: 10.3389/fonc.2023.1167266.

Facing challenges with hope: universal immune cells for hematologic malignancies.

Wang Y, Huang R, Wang Z, Xiong J, Wang X, Zhang X Cancer Biol Med. 2023; 20(4).

PMID: 37144558 PMC: 10157807. DOI: 10.20892/j.issn.2095-3941.2022.0759.

Personalize, participate, predict, and prevent: 4Ps in inflammatory bowel disease.

Lenti M, Scribano M, Biancone L, Ciccocioppo R, Pugliese D, Pastorelli L Front Med (Lausanne). 2023; 10:1031998.

PMID: 37113615 PMC: 10126747. DOI: 10.3389/fmed.2023.1031998.

References

McLaughlin L, Lang H, Williams E, Wright K, Powell A, Cruz C . Human parainfluenza virus-3 can be targeted by rapidly ex vivo expanded T lymphocytes. Cytotherapy. 2016; 18(12):1515-1524. PMC: 5096976. DOI: 10.1016/j.jcyt.2016.08.010. View

Vasileiou S, Turney A, Kuvalekar M, Mukhi S, Watanabe A, Lulla P . Rapid generation of multivirus-specific T lymphocytes for the prevention and treatment of respiratory viral infections. Haematologica. 2019; 105(1):235-243. PMC: 6939529. DOI: 10.3324/haematol.2018.206896. View

Boeckh M, Nichols W, Papanicolaou G, Rubin R, Wingard J, Zaia J . Cytomegalovirus in hematopoietic stem cell transplant recipients: Current status, known challenges, and future strategies. Biol Blood Marrow Transplant. 2003; 9(9):543-58. DOI: 10.1016/s1083-8791(03)00287-8. View

Gerdemann U, Katari U, Papadopoulou A, Keirnan J, Craddock J, Liu H . Safety and clinical efficacy of rapidly-generated trivirus-directed T cells as treatment for adenovirus, EBV, and CMV infections after allogeneic hematopoietic stem cell transplant. Mol Ther. 2013; 21(11):2113-21. PMC: 3831033. DOI: 10.1038/mt.2013.151. View

Sehn L, Goy A, Offner F, Martinelli G, Caballero M, Gadeberg O . Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study. J Clin Oncol. 2015; 33(30):3467-74. PMC: 5087315. DOI: 10.1200/JCO.2014.59.2139. View

Leen A, Bollard C, Mendizabal A, Shpall E, Szabolcs P, Antin J . Multicenter study of banked third-party virus-specific T cells to treat severe viral infections after hematopoietic stem cell transplantation. Blood. 2013; 121(26):5113-23. PMC: 3695359. DOI: 10.1182/blood-2013-02-486324. View

Boeckh M, Leisenring W, Riddell S, Bowden R, Huang M, Myerson D . Late cytomegalovirus disease and mortality in recipients of allogeneic hematopoietic stem cell transplants: importance of viral load and T-cell immunity. Blood. 2002; 101(2):407-14. DOI: 10.1182/blood-2002-03-0993. View

Uhlin M, Gertow J, Uzunel M, Okas M, Berglund S, Watz E . Rapid salvage treatment with virus-specific T cells for therapy-resistant disease. Clin Infect Dis. 2012; 55(8):1064-73. DOI: 10.1093/cid/cis625. View

Withers B, Blyth E, Clancy L, Yong A, Fraser C, Burgess J . Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells. Blood Adv. 2018; 1(24):2193-2205. PMC: 5737128. DOI: 10.1182/bloodadvances.2017010223. View

10.

Bollard C, Heslop H . T cells for viral infections after allogeneic hematopoietic stem cell transplant. Blood. 2016; 127(26):3331-40. PMC: 4929925. DOI: 10.1182/blood-2016-01-628982. View

11.

Ma C, Clancy L, Deo S, Blyth E, Micklethwaite K, Gottlieb D . Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy. Cytotherapy. 2016; 19(1):107-118. DOI: 10.1016/j.jcyt.2016.09.013. View

12.

Heslop H, Slobod K, Pule M, Hale G, Rousseau A, Smith C . Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients. Blood. 2009; 115(5):925-35. PMC: 2817637. DOI: 10.1182/blood-2009-08-239186. View

13.

Keller M, Darko S, Lang H, Ransier A, Lazarski C, Wang Y . T-cell receptor sequencing demonstrates persistence of virus-specific T cells after antiviral immunotherapy. Br J Haematol. 2019; 187(2):206-218. PMC: 6786907. DOI: 10.1111/bjh.16053. View

14.

Lee D, Gardner R, Porter D, Louis C, Ahmed N, Jensen M . Current concepts in the diagnosis and management of cytokine release syndrome. Blood. 2014; 124(2):188-95. PMC: 4093680. DOI: 10.1182/blood-2014-05-552729. View

15.

Hiwarkar P, Amrolia P, Sivaprakasam P, Lum S, Doss H, ORafferty C . Brincidofovir is highly efficacious in controlling adenoviremia in pediatric recipients of hematopoietic cell transplant. Blood. 2017; 129(14):2033-2037. DOI: 10.1182/blood-2016-11-749721. View

16.

Haque T, Taylor C, Wilkie G, Murad P, Amlot P, Beath S . Complete regression of posttransplant lymphoproliferative disease using partially HLA-matched Epstein Barr virus-specific cytotoxic T cells. Transplantation. 2001; 72(8):1399-402. DOI: 10.1097/00007890-200110270-00012. View

17.

Cortese I, Muranski P, Enose-Akahata Y, Ha S, Smith B, Monaco M . Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy. N Engl J Med. 2019; 380(17):1597-1605. DOI: 10.1056/NEJMoa1815039. View

18.

Rooney C, Smith C, Ng C, Loftin S, Sixbey J, Gan Y . Infusion of cytotoxic T cells for the prevention and treatment of Epstein-Barr virus-induced lymphoma in allogeneic transplant recipients. Blood. 1998; 92(5):1549-55. View

19.

Miller H, Hanley P, Lang H, Lazarski C, Chorvinsky E, McCormack S . Antiviral T Cells for Adenovirus in the Pretransplant Period: A Bridge Therapy for Severe Combined Immunodeficiency. Biol Blood Marrow Transplant. 2018; 24(9):1944-1946. PMC: 6387568. DOI: 10.1016/j.bbmt.2018.04.030. View

20.

Tzannou I, Nicholas S, Lulla P, Aguayo-Hiraldo P, Misra A, Martinez C . Immunologic Profiling of Human Metapneumovirus for the Development of Targeted Immunotherapy. J Infect Dis. 2017; 216(6):678-687. PMC: 5853664. DOI: 10.1093/infdis/jix358. View